# Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

> **NCT06462053** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 134 (estimated)

## Conditions studied

- Early Low Rectal Cancer

## Interventions

- **RADIATION:** Short-course radiotherapy
- **DRUG:** PD-1 antibody (Toripalimab)
- **RADIATION:** Long-course radiotherapy
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06462053
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462053, "Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06462053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*